National Institute on Drug Abuse

NIH funds research network focused on HIV-infected youth

Monday, September 26, 2016

The NIH has awarded funding for a research network devoted to the health and well-being of adolescents and young adults with HIV or at risk for HIV infection. The awards, up to $24 million in 2016, provide for three research centers and a data coordinating center that will make up the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN).

[Read More]

Embera wins $11M NIDA grant for cocaine addiction treatment EMB-001

Wednesday, July 27, 2016

Embera NeuroTherapeutics, a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, has received an $11.1 million, three-year grant from the National Institute on Drug Abuse (NIDA), part of the NIH. The grant will support continued clinical development of EMB-001 for the treatment of cocaine addiction, which is clinically termed “cocaine use disorder.”

[Read More]

NIH expands investment in HIV cure research

Tuesday, July 19, 2016

The NIH has awarded approximately $30 million in annual funding over the next five years to six research collaborations working to advance basic medical science toward an HIV cure. The awards comprise the second iteration of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research. The research program is supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, all part of the NIH.

[Read More]

FDA approves first buprenorphine implant for opioid dependence

Friday, May 27, 2016

The FDA has approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

[Read More]

NIH Common Fund launches biomed programs

Monday, October 5, 2015

The NIH Common Fund has awarded more than $54 million in fiscal year 2015 to launch projects in four broad scientific areas: the Glycoscience Program, the 4D Nucleome Program, the Gabriella Miller Kids First Research Program and the Science of Behavior Change Program. The Common Fund planning process identifies major challenges that impede progress in research and emerging areas of science that promise to change the way people think about health and disease or the way prevention or treatment is approached. Common Fund programs that emerge are goal-driven, with deliverables expected within a five to 10 year period. The 2015 awards represented first-year funding of a multiyear program.

[Read More]

Verified Clinical Trials inks two partner agreements

Thursday, August 13, 2015

AXIS Clinicals USA, a Dilworth, Minn.-based CRO, has partnered with the Verified Clinical Trials (VCT) national clinical trial database registry to stop attempts at dual enrollment in clinical trial research, thus preventing protocol deviations, improving data quality and promoting subject safety. Within the first seven days of use, the VCT system proved its worth by stopping a subject’s attempt at dual enrollment. VCT is the largest North American database registry in both early and late phase clinical trials.

[Read More]

AiCure tests artificial intelligence in opioid trial

Monday, November 24, 2014

AiCure, a New York-based artificial intelligence company providing advanced facial recognition and motion-sensing technology to monitor medication ingestion, has announced the start of a major clinical trial to monitor and intervene with patients receiving medication as maintenance therapy for opioid addiction.

[Read More]